Hemosol B0

HemoSol B0 is an intravenous electrolyte solution formulated with calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied in a sterile liquid form intended for infusion in clinical settings. The product complies with European Union pharmaceutical standards and is marketed without a specific brand name. HemoSol B0 provides a balanced mix of essential ions to support physiological electrolyte and acid‑base homeostasis during patient care.

HemoSol B0 is used in clinical practice to address electrolyte and acid‑base disturbances when intravenous therapy is required.

- Replacement of calcium and magnesium losses during surgery or trauma. - Correction of metabolic acidosis by providing bicarbonate precursors. - Support of plasma electrolyte balance in patients receiving large-volume fluid resuscitation. - Adjunctive therapy for patients with renal replacement therapy or dialysis. - Management of hypochloremia or hyponatremia in critical care settings.

Adverse reactions to HemoSol B0 are generally infrequent, but they may occur with any intravenous solution.

Common: - Mild infusion site irritation or erythema. - Transient nausea or vomiting. - Slight increase in serum calcium or magnesium levels without clinical significance. - Temporary feeling of warmth or flushing during administration. - Mild headache or dizziness during infusion.

Serious: - Hypercalcemia or hypermagnesemia leading to cardiac arrhythmia. - Severe metabolic alkalosis from excess bicarbonate. - Anaphylactic or severe allergic reaction manifesting as hypotension, bronchospasm, or urticaria. - Pulmonary edema due to rapid infusion of large volumes. - Acute renal impairment associated with electrolyte imbalance.

When using HemoSol B0, clinicians should observe specific precautions to minimize risks and ensure appropriate patient monitoring.

- Assess baseline serum electrolytes, especially calcium, magnesium, sodium, and chloride, before initiation. - Adjust infusion rate according to patient volume status and cardiac function. - Avoid rapid administration in patients at risk for fluid overload or pulmonary edema. - Monitor arterial blood gases and acid‑base status during therapy. - Use caution in patients with renal insufficiency or on dialysis. - Discontinue if signs of hypercalcemia, hypermagnesemia, or severe alkalosis develop. - Document any adverse reactions in the patient record.

HemoSol B0 may interact with other intravenous medications or solutions, requiring careful coordination of therapy.

Avoid: - Concurrent infusion with calcium‑binding agents such as bisphosphonates, which can reduce calcium availability. - Simultaneous administration of high‑dose sodium bicarbonate, which may exacerbate metabolic alkalosis.

Use with caution: - Co‑administration with loop diuretics, as they can amplify electrolyte shifts. - Use alongside cardiotoxic drugs (e.g., digoxin) when serum calcium is elevated. - Combination with other magnesium‑containing solutions, to prevent hypermagnesemia. - Overlap with blood products that contain citrate, which may affect calcium levels.